|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.160 USD | +8.41% |
|
+3.57% | -14.07% |
| Dec. 19 | CbdMD, Inc., Q4 2025 Earnings Call, Dec 19, 2025 | |
| Dec. 19 | CbdMD, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 | CI |
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | -10.4 | -13.06 | -20.33 | -15.48 | -12.87 | |||
Return on Total Capital | -12.44 | -14.87 | -23.64 | -25.99 | -24.05 | |||
Return On Equity % | -25.66 | -104.16 | -113.4 | -67.31 | -44.42 | |||
Return on Common Equity | -28.47 | -110.12 | -133.22 | -140.27 | -95.3 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | 67.41 | 63.09 | 62.01 | 61.57 | 62.37 | |||
SG&A Margin | 100.99 | 111.99 | 71.89 | 68.09 | 62.49 | |||
EBITDA Margin % | -41.81 | -43.72 | -30.92 | -11.12 | -5.4 | |||
EBITA Margin % | -43.99 | -46.4 | -32.59 | -13.44 | -7.28 | |||
EBIT Margin % | -44.1 | -48.9 | -38.37 | -17.02 | -11.27 | |||
Income From Continuing Operations Margin % | -52.6 | -197.96 | -94.96 | -18.99 | -10.63 | |||
Net Income Margin % | -52.6 | -197.96 | -94.96 | -18.99 | -10.63 | |||
Net Avail. For Common Margin % | -58.34 | -209.26 | -111.53 | -39.54 | -22.8 | |||
Normalized Net Income Margin | -27.56 | -30.11 | -23.82 | -10.73 | -6.93 | |||
Levered Free Cash Flow Margin | -16.81 | -26.5 | -2.55 | 29.65 | -25.66 | |||
Unlevered Free Cash Flow Margin | -16.77 | -26.5 | -2.55 | 29.74 | -25.66 | |||
Asset Turnover | ||||||||
Asset Turnover | 0.38 | 0.43 | 0.85 | 1.46 | 1.83 | |||
Fixed Assets Turnover | 4.88 | 5.25 | 5.16 | 8.46 | 25.23 | |||
Receivables Turnover (Average Receivables) | 43.93 | 27.65 | 18.14 | 17.71 | 18.96 | |||
Inventory Turnover (Average Inventory) | 2.77 | 2.53 | 2.04 | 2.22 | 2.64 | |||
Short Term Liquidity | ||||||||
Current Ratio | 5.28 | 3.03 | 1.73 | 0.74 | 2.05 | |||
Quick Ratio | 4.13 | 1.73 | 0.65 | 0.4 | 1.03 | |||
Operating Cash Flow to Current Liabilities | -2.04 | -2.83 | -0.92 | -0.04 | -0.45 | |||
Days Sales Outstanding (Average Receivables) | 8.31 | 13.2 | 20.13 | 20.66 | 19.26 | |||
Days Outstanding Inventory (Average Inventory) | 131.76 | 144.43 | 179.03 | 165.23 | 138.25 | |||
Average Days Payable Outstanding | 70.1 | 74.66 | 83.23 | 109.24 | 64.81 | |||
Cash Conversion Cycle (Average Days) | 69.97 | 82.98 | 115.93 | 76.66 | 92.7 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 5.88 | 15.5 | 40.78 | 64.68 | 10.77 | |||
Total Debt / Total Capital | 5.56 | 13.42 | 28.97 | 39.28 | 9.72 | |||
LT Debt/Equity | 4.71 | 11.72 | 26.61 | - | - | |||
Long-Term Debt / Total Capital | 4.45 | 10.15 | 18.9 | - | - | |||
Total Liabilities / Total Assets | 17.41 | 22.96 | 44.24 | 81.44 | 30.65 | |||
EBIT / Interest Expense | -678.05 | - | - | -112.36 | - | |||
EBITDA / Interest Expense | -589.4 | - | - | 17.36 | - | |||
(EBITDA - Capex) / Interest Expense | -601.23 | - | - | 10.92 | - | |||
Total Debt / EBITDA | -0.36 | -0.35 | -0.6 | 2.48 | 2.21 | |||
Net Debt / EBITDA | 1.25 | 0.2 | -0.31 | -2.31 | -4.21 | |||
Total Debt / (EBITDA - Capex) | -0.35 | -0.33 | -0.57 | 3.94 | 4.63 | |||
Net Debt / (EBITDA - Capex) | 1.23 | 0.19 | -0.29 | -3.67 | -8.82 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | 6.2 | -20.41 | -31.77 | -19.35 | -1.5 | |||
Gross Profit, 1 Yr. Growth % | 13.72 | -25.51 | -32.95 | -19.91 | -0.23 | |||
EBITDA, 1 Yr. Growth % | 10.3 | -16.78 | -51.75 | -71 | -52.14 | |||
EBITA, 1 Yr. Growth % | 11.29 | -16.26 | -52.08 | -66.74 | -46.62 | |||
EBIT, 1 Yr. Growth % | 11.57 | -11.75 | -46.46 | -64.23 | -34.77 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | -284.92 | 199.57 | -67.27 | -83.87 | -44.84 | |||
Net Income, 1 Yr. Growth % | -285.64 | 199.57 | -67.27 | -83.87 | -44.84 | |||
Normalized Net Income, 1 Yr. Growth % | 11.82 | -13.05 | -46.03 | -63.66 | -36.37 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | -269.72 | 162.52 | -76.13 | -86.56 | -92.39 | |||
Accounts Receivable, 1 Yr. Growth % | 22.15 | 30.04 | -16.01 | -19.09 | 5.79 | |||
Inventory, 1 Yr. Growth % | 13.94 | -14.46 | -11.15 | -40.41 | 16.75 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | -18.52 | -35.17 | -23.27 | -86.72 | 81.7 | |||
Total Assets, 1 Yr. Growth % | 12.67 | -67.34 | -60.3 | -34.66 | -1.53 | |||
Tangible Book Value, 1 Yr. Growth % | 715.64 | -42.1 | -57.25 | -116.03 | -647.69 | |||
Common Equity, 1 Yr. Growth % | 30.25 | -69.54 | -71.27 | -78.3 | 268.89 | |||
Cash From Operations, 1 Yr. Growth % | 32.15 | 6.2 | -71.26 | -91.8 | 311.68 | |||
Capital Expenditures, 1 Yr. Growth % | -74.09 | 101.36 | -56.79 | -36.14 | -3.08 | |||
Levered Free Cash Flow, 1 Yr. Growth % | 66.79 | 25.42 | -92.54 | -484.89 | -185.26 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 66.39 | 25.72 | -92.54 | -486.12 | -184.99 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 37.14 | -8.06 | -26.31 | -25.82 | -10.87 | |||
Gross Profit, 2 Yr. CAGR % | 43.73 | -7.96 | -29.33 | -26.72 | -10.61 | |||
EBITDA, 2 Yr. CAGR % | 14.88 | -4.19 | -36.63 | -62.59 | -62.75 | |||
EBITA, 2 Yr. CAGR % | 17.05 | -3.34 | -36.65 | -60.08 | -57.87 | |||
EBIT, 2 Yr. CAGR % | 16.88 | -0.77 | -31.26 | -56.24 | -51.7 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | -28.24 | 135.36 | -0.98 | -77.02 | -70.17 | |||
Net Income, 2 Yr. CAGR % | -31.89 | 135.82 | -0.98 | -77.02 | -70.17 | |||
Normalized Net Income, 2 Yr. CAGR % | 17.18 | -1.4 | -31.5 | -55.71 | -51.92 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | -56.87 | 111.08 | -20.83 | -82.09 | -89.9 | |||
Accounts Receivable, 2 Yr. CAGR % | -11.63 | 26.03 | 4.51 | -17.56 | -7.48 | |||
Inventory, 2 Yr. CAGR % | 3.48 | -1.28 | -12.82 | -27.24 | -16.59 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | 118.31 | -27.32 | -29.47 | -68.08 | -50.88 | |||
Total Assets, 2 Yr. CAGR % | 14.95 | -39.34 | -63.99 | -49.07 | -19.79 | |||
Tangible Book Value, 2 Yr. CAGR % | -22.14 | 117.32 | -50.25 | -73.82 | -6.29 | |||
Common Equity, 2 Yr. CAGR % | 65.61 | -37.01 | -70.42 | -75.03 | -10.54 | |||
Cash From Operations, 2 Yr. CAGR % | -4.27 | 18.47 | -44.75 | -84.65 | -41.9 | |||
Capital Expenditures, 2 Yr. CAGR % | -46.58 | -27.77 | -6.73 | -47.47 | -21.33 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | -9.78 | 44.63 | -71.31 | -16.35 | 81.15 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -9.89 | 44.63 | -71.27 | -16.22 | 81.15 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | 359.29 | 14.39 | -16.76 | -24.06 | -18.46 | |||
Gross Profit, 3 Yr. CAGR % | 338.73 | 15.45 | -17.18 | -26.32 | -18.78 | |||
EBITDA, 3 Yr. CAGR % | 126.31 | 3.17 | -23.77 | -51.17 | -59.39 | |||
EBITA, 3 Yr. CAGR % | 129.88 | 4.78 | -23.5 | -48.9 | -56.02 | |||
EBIT, 3 Yr. CAGR % | 121.83 | 6.43 | -19.22 | -44.71 | -50.01 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 135.24 | 15.55 | 21.94 | -45.92 | -69.23 | |||
Net Income, 3 Yr. CAGR % | 284.34 | 11.6 | 22.1 | -45.92 | -69.23 | |||
Normalized Net Income, 3 Yr. CAGR % | 121.83 | 6.09 | -19.34 | -44.55 | -50.03 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | 26.72 | -21.26 | 2.08 | -56.17 | -86.54 | |||
Accounts Receivable, 3 Yr. CAGR % | -15.51 | 0.51 | 10.09 | -4.04 | -10.42 | |||
Inventory, 3 Yr. CAGR % | - | -2.89 | -4.69 | -23.2 | -14.82 | |||
Net Property, Plant and Equip., 3 Yr. CAGR % | 1.11K | 45.65 | -25.99 | -59.58 | -43.01 | |||
Total Assets, 3 Yr. CAGR % | 102.6 | -24.43 | -47.33 | -56.08 | -36.55 | |||
Tangible Book Value, 3 Yr. CAGR % | 24.37 | -29.46 | 26.39 | -65.89 | -27.86 | |||
Common Equity, 3 Yr. CAGR % | 101.5 | -5.81 | -51.51 | -73.32 | -38.74 | |||
Cash From Operations, 3 Yr. CAGR % | 36.24 | -0.9 | -26.11 | -70.75 | -54.05 | |||
Capital Expenditures, 3 Yr. CAGR % | 143.95 | -16.87 | -39.14 | -17.79 | -35.57 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | 0.69 | -48.41 | -8.25 | -15.82 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | 0.69 | -48.41 | -8.08 | -15.82 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 120.91 | -3.8 | -14.45 | |||
Gross Profit, 5 Yr. CAGR % | - | - | 111.36 | -3.74 | -14.61 | |||
EBITDA, 5 Yr. CAGR % | - | - | 36.01 | -31.24 | -42.76 | |||
EBITA, 5 Yr. CAGR % | - | - | 37.34 | -28.77 | -39.74 | |||
EBIT, 5 Yr. CAGR % | - | - | 38.83 | -25.41 | -34.24 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 66.42 | -39.44 | -30.57 | |||
Net Income, 5 Yr. CAGR % | - | - | 123.42 | -40.69 | -30.52 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 38.64 | -25.2 | -34.42 | |||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | 4.99 | -56.45 | -59.53 | |||
Accounts Receivable, 5 Yr. CAGR % | - | - | -8.01 | -7.15 | 2.69 | |||
Inventory, 5 Yr. CAGR % | - | - | - | -13.48 | -9.64 | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | 288.33 | -20.64 | -37.19 | |||
Total Assets, 5 Yr. CAGR % | - | - | 1.52 | -35.46 | -37.68 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | -13.79 | -52.55 | 12.13 | |||
Common Equity, 5 Yr. CAGR % | - | - | -6.46 | -44.62 | -38.05 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | -5.05 | -53 | -32.88 | |||
Capital Expenditures, 5 Yr. CAGR % | - | - | 66.07 | -30.81 | -32.56 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | -8.87 | 1.89 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | -8.81 | 1.89 |
- Stock Market
- Equities
- YCBD Stock
- Financials cbdMD, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















